Patents Assigned to Nalpropion Pharmaceuticals LLC
-
Publication number: 20230301922Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.Type: ApplicationFiled: May 4, 2023Publication date: September 28, 2023Applicant: Nalpropion Pharmaceuticals LLCInventors: Anthony A. McKinney, Gary D. Tollefson, Eckard Weber, Richard Soltero
-
Publication number: 20220233520Abstract: Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy.Type: ApplicationFiled: April 11, 2022Publication date: July 28, 2022Applicant: Nalpropion Pharmaceuticals LLCInventors: Shawn Flanagan, Eduardo Dunayevich
-
Publication number: 20220208327Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.Type: ApplicationFiled: October 4, 2021Publication date: June 30, 2022Applicant: Nalpropion Pharmaceuticals LLCInventors: Preston Klassen, Kristin Taylor
-
Publication number: 20220202808Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: March 21, 2022Publication date: June 30, 2022Applicant: Nalpropion Pharmaceuticals LLCInventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 11324741Abstract: Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.Type: GrantFiled: March 1, 2017Date of Patent: May 10, 2022Assignee: Nalpropion Pharmaceuticals LLCInventor: Gary D. Tollefson
-
Publication number: 20220105087Abstract: Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy.Type: ApplicationFiled: December 15, 2021Publication date: April 7, 2022Applicant: Nalpropion Pharmaceuticals LLCInventors: Shawn Flanagan, Eduardo Dunayevich
-
Publication number: 20220088007Abstract: Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy.Type: ApplicationFiled: June 9, 2021Publication date: March 24, 2022Applicant: Nalpropion Pharmaceuticals LLCInventors: Shawn Flanagan, Eduardo Dunayevich
-
Patent number: 11278544Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: March 25, 2019Date of Patent: March 22, 2022Assignee: Nalpropion Pharmaceuticals LLCInventors: Eckard Weber, Michael Alexander Cowley
-
Publication number: 20210346469Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.Type: ApplicationFiled: June 1, 2021Publication date: November 11, 2021Applicant: Nalpropion Pharmaceuticals LLCInventors: Michael Alexander Cowley, Anthony A. McKinney, Gary D. Tollefson
-
Patent number: 11139056Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.Type: GrantFiled: September 2, 2019Date of Patent: October 5, 2021Assignee: Nalpropion Pharmaceuticals LLCInventors: Preston Klassen, Kristin Taylor
-
Publication number: 20210299119Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.Type: ApplicationFiled: June 14, 2021Publication date: September 30, 2021Applicant: Nalpropion Pharmaceuticals LLCInventors: Eduardo Dunayevich, Gary D. Tollefson
-
Publication number: 20210283126Abstract: Compositions, uses, kits and methods for reducing hinge or compulsive eating are described herein. Methods may include administering an effective combination of a dosage of a bupropion or a pharmaceutically acceptable salt thereof, and a dosage of naltrexone or a pharmaceutically acceptable salt thereof. Methods may include identifying a patient who is overweight or obese and providing an effective combination of bupropion and naltrexone to the patient. Methods may include reducing a number of binge or compulsive eating events. Methods may include reducing severity of binge or compulsive eating events.Type: ApplicationFiled: June 2, 2021Publication date: September 16, 2021Applicant: Nalpropion Pharmaceuticals LLCInventors: Eduardo Dunayevich, Susan McElroy, Ron Landbloom
-
Publication number: 20210267968Abstract: Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an ?-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: ApplicationFiled: May 13, 2021Publication date: September 2, 2021Applicant: Nalpropion Pharmaceuticals LLCInventors: Anthony A. McKinney, Gary D. Tollefson, Michael Alexander Cowley
-
Patent number: 11033543Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.Type: GrantFiled: June 14, 2019Date of Patent: June 15, 2021Assignee: Nalpropion Pharmaceuticals LLCInventors: Eduardo Dunayevich, Gary Tollefson
-
Publication number: 20210069181Abstract: The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable alts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovasular outcomes or MACE, wherein the treatment reduce, the risk of MACE.Type: ApplicationFiled: November 16, 2020Publication date: March 11, 2021Applicant: Nalpropion Pharmaceuticals LLCInventors: Preston Klassen, Kristin Taylor
-
Patent number: 10835527Abstract: The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.Type: GrantFiled: March 18, 2019Date of Patent: November 17, 2020Assignee: Nalpropion Pharmaceuticals LLCInventors: Preston Klassen, Kristin Taylor
-
Patent number: 10828294Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.Type: GrantFiled: March 18, 2019Date of Patent: November 10, 2020Assignee: Nalpropion Pharmaceuticals LLCInventors: Preston Klassen, Kristin Taylor